AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 61 min read$LH

Summy Amy B. sold $283K of LH

Summy Amy B. (EVP, Chief Marketing Officer) sold 924 shares of LABCORP HOLDINGS INC. (LH) at $306.74 ($0.28M total) on 2026-08-04.

Original reporting
SEC EDGAR · Summy Amy B.
Published Aug 6, 2026, 12:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The disclosure updates insider trading records but does not introduce new company performance, guidance, or regulatory developments.

02

Market read

Traders may note the sale for sentiment, but it is unlikely to change valuation without additional corroborating news.

03

What to watch

The article does not indicate whether the sale was tax-related, diversification-driven, or part of a broader pattern; also no 10b5-1 plan was used per the text.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06, transaction dated 2026-08-04

Background

SEC Form 4 insider transaction for LABCORP HOLDINGS INC. (LH) by EVP and Chief Marketing Officer Summy Amy B.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH CMO Summy Amy B. sold 924 shares at $306.74 on 2026-08-04, totaling $283,427.76.

Expected impact

Minimal near-term impact; any reaction is likely noise unless paired with other disclosures.

Evidence & confidence

This is a single insider sale, not a buy, not tied to new company guidance, and the filing provides no new operational or financial information.

Market effects

Sector

No clear sector read-through from a single marketing executive’s sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can sometimes precede negative developments, but this filing lacks any accompanying company-specific catalyst.

Key entities

  • issuer
    LABCORP HOLDINGS INC.

    Company subject of the Form 4 insider sale disclosure.

  • insider
    Summy Amy B.

    EVP, Chief Marketing Officer who sold 924 shares.

Read at source← All news

Related articles

AUG 5
$LHMed

Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Labcorp said it has nationwide availability of Roche’s Ventana PTEN (SP218) RxDx immunohistochemistry companion diagnostic, FDA approved to detect PTEN protein loss in prostate adenocarcinoma. The result helps identify patients eligible for AstraZeneca’s TRUQAP (capivasertib) plus abiraterone acetate and prednisone. Labcorp says it supports personalized treatment decisions via its lab network.

clpmag.com3 min
AUG 5
$LHMed

LABCORP HOLDINGS 2026: Revenue $3.73B, EPS $3.64— 10-Q Summary

Labcorp Holdings (LH) reported Q2 2026 revenue of $3.73B and diluted EPS of $3.64, up from $3.53B and $2.84 a year earlier, according to its 10-Q. The company cited higher test utilization, price and mix gains, and margin expansion, plus 4.2% organic growth and acquisition contributions. It also increased capital spending and completed acquisitions.

tradingview.com1 min
AUG 5
$LHMed

Labcorp launches FDA-approved PTEN test for prostate cancer

Labcorp (NYSE:LH) said the FDA-approved Roche VENTANA PTEN (SP218) RxDx Assay is now available nationwide. The test detects PTEN protein loss in prostate adenocarcinoma tissue to identify patients who may qualify for AstraZeneca’s TRUQAP (capivasertib) with abiraterone and prednisone, according to Labcorp. The assay is offered via Labcorp’s lab network.

investing.com3 min
AUG 4
$LHMedAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Labcorp (LH) reported Q2 2026 enterprise revenue of $3.7B, up 5.8% YoY, with adjusted EPS of $4.99, up 14.9%. Adjusted operating margin rose to 15.8%. Free cash flow was $314M. The company raised full-year guidance for revenue and adjusted EPS, citing Diagnostics and Central Laboratories strength, and noted ACA headwinds.

fool.com10 min
JUL 31
$LHHighAI 9/10

Labcorp (LH) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Dewey Steadman Chairman and Chief Executive Officer - Adam Schechter Executive Vice President and Chief Financial Officer - Julia Wang TAKEAWAYS Enterprise Revenue -- $3.7 billion, up 5.8% year over year, driven by 4.2% organic growth and 1.2% contribution from net acquisitions.

fool.com6 min